Search Results - barbara+slusher

13 Results

Sort By:

Prodrug for Immunological and Oncological Therapy

Unmet NeedApproximately 1.24 million hematological cancer cases occur each year, accounting for approximately 6% of all cancer cases (Bristol Myers Squibb). Currently, standard treatment strategies include chemotherapy, radiation therapy, and stem cell transplants. However, there exist several major drawbacks for each method. Stem cell transplants can...

Published: 5/9/2024 | Inventor(s): Barbara Slusher, Rana Rais, Franco D'alessio, Pavel Majer, Marcela Krecmerova, Srinivasan Yegnasubramanian

Keywords(s): Blood Cancer, Cancers, Disease Indication, Inflammatory Disorders, Respiratory Infections, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutic Substance Synthesis Method, Therapeutics, Transplants

Category(s): Clinical and Disease Specializations > Oncology > Hematologic Malignancies, Clinical and Disease Specializations > Transplantation, Technology Classifications > Therapeutic Modalities > Small Molecules

GCPII Inhibition for the Treatment of Sarcopenia and Aging

Unmet Need:Sarcopenia is the progressive loss of muscle mass and function, and is a natural part of the aging process. Age-related muscle loss and weakness can contribute to frailty and increase the likelihood of falls and fractures in older adults. Recent reports found that 5-13% of persons over the age of 65 years and >50% of people 80 years and...

Published: 5/10/2024 | Inventor(s): Barbara Slusher, Carolyn Tallon

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Geriatrics

DOPA and Caffeic Acid Analogs as Novel GCPII Inhibitors

Unmet NeedGlutamate is the primary excitatory neurotransmitter in the human brain [1]. Excessive glutamate signaling can disrupt calcium homeostasis, leading to mitochondrial dysfunction, the overproduction of reactive oxygen species, and neuron loss via necrotic or apoptotic pathways [2]. This phenomenon, known as excitotoxicity, contributes to disease...

Published: 5/10/2024 | Inventor(s): Barbara Slusher, Rana Rais, Takashi Tsukamoto

Keywords(s):

Category(s): Clinical and Disease Specializations > Neurology, Technology Classifications, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Small Molecules

Preventing Acute Kidney Injury Using JHU083

Unmet Need: It is estimated that 13.3 million people worldwide are affected by acute kidney injury (AKI) (see Bjornstad et. al). AKI is an especially prevalent condition in kidney transplant recipients, with one study showing that 35% of recipients had at least one episode of AKI (see Palmisiano et. al). These injury events lead to worsening kidney...

Published: 5/10/2024 | Inventor(s): Hamid Rabb, Barbara Slusher, Jonathan Powell, Kyungho Lee, Elizabeth Thompson, Sanjeev Noel, Sepideh Gharaie

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Nephrology

Methods to Treat Neurodegenerative Diseases

Unmet NeedAn estimated 930K people in the US are living with a neurodegenerative disease (Alzheimer’s and Parkinson’s are most common). However, current standard of care treatments mostly addresses symptoms of these diseases. To date no disease modifying or neuroprotective treatments are approved for Parkinson, and only 1 recently has been for Alzheimer’s...

Published: 5/10/2024 | Inventor(s): Rana Rais, Barbara Slusher, Arindom Pal

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Neurology > Multiple Sclerosis, Clinical and Disease Specializations > Neurology > Amyotrophic Lateral Sclerosis, Clinical and Disease Specializations > Neurology > HIV-Associated Neurocognitive Disorders

Discovery of 2,6-Dimethoxy-4-(5-Phenyl-4-Thiophen-2-yl-1H-Imidazol-2-yl)-Phenol (DPTIP) a Small Molecule Inhibitor of Neutral Sphingomyelinase 2 (nSMase2) for the Treatment of Neurodegenerative and Oncologic Diseases

Unmet NeedAlzheimer’s disease (AD) is the most common form of dementia, affecting approximately 5.7 million people in the United States in 2018. Yet, no cure exists for AD, and AD therapeutics presently on the market fail to treat the disease’s underlying causes. Recent studies in mice reveal that exosomes released from glial cells contribute to the...

Published: 5/9/2024 | Inventor(s): Barbara Slusher, Camilo Rojas, Ajit Thomas, Norman Haughey, Marc Ferrer, Xin Hu

Keywords(s): Antagonists/Inhibitors, Cancers, CNS and Neurological Disorders, Disease Indication, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules

Glutamine Antagonists for the Treatment of Cognitive Deficits, including NeuroAIDs

Some glutamine antagonists have been shown to have anti-cancer activities in multiple preclinical and clinical studies. However the toxicity of the glutamine antagonists at doses necessary for their anticancer effects have hampered their clinical development. Herein we describe a completely novel use for the glutamine antagonists. Using a prototype...

Published: 5/9/2024 | Inventor(s): Barbara Slusher, David Volsky, Kristen Hollinger, Michael Nedelcovych, Atsushi Kamiya

Keywords(s): Antagonists/Inhibitors, CNS and Neurological Disorders, Cognitive Impairment, Disease Indication, HIV/AIDS, HIV-Associated Neurocognitive Disorders, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases > HIV/AIDS, Clinical and Disease Specializations > Neurology > Cognitive Impairment, Clinical and Disease Specializations > Neurology > HIV-Associated Neurocognitive Disorders, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Infectious Diseases, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities

Intranasal Administration of Glutamate Carboxypeptidase (GCP-II) Inhibitors for Enhanced Brain Delivery

Inventors have developed a novel method to enhance the penetrance of multiple GCPII inhibitors which were developed by the inventor and Dr. Pomper at JHU. This method demonstrated improved brain penetrance in rodents. The penetrance of a specific GCPII inhibitor showed significant brain penetrance in non-human primates and inhibited GCPII activity in...

Published: 5/9/2024 | Inventor(s): Rana Rais, Barbara Slusher

Keywords(s): Biologics, CNS and Neurological Disorders, Disease Indication, Drug Delivery Mechanism, Enzyme, Imaging Agent, Imaging and Sensing Systems, Imaging Modality, In Vivo Medical Imaging, Intranasal Administration, Multiple CNS Indications, Positron Emission Tomography (PET), Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Medical Devices > Imaging, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Medical Devices, Technology Classifications > Therapeutic Modalities

Quantitation of GCPII Enzymatic Activity in Human Skin Biopsies as a Clinical Biomarker

We have identified a unique tissue preparation and enzymatic assay conditions to quatitatively monitor glutamate carboxypeptidase II (GCPII) activity in human skin biopsy samples. This assay can be utilzed as a phanacodynamic (PD) marker in the clinical development of novel GCPII inhibitors. This new assay is a significant improvement over GCPII biomarker...

Published: 5/9/2024 | Inventor(s): Barbara Slusher, Camilo Rojas, Marigo Stathis, Michael Polydefkis

Keywords(s): Assay, Biomarker, Clinical Diagnostics, CNS and Neurological Disorders, Disease Indication, In Vitro Diagnostics, Multiple CNS Indications, Pharmakodynamic Biomarker, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities

Buccal and Intranasal Delivery of Fospropofol

INVENTION NOVELTY This invention provides for novel formulations and delivery methods of the propofol prodrug, fospropofol, allowing for its use in additional indications beyond anesthesia, including migraine, analgesia, and emesis treatment. VALUE PROPOSITION Propofol and its water soluble prodrug, fospropofol, are short-acting anesthetics used...

Published: 5/9/2024 | Inventor(s): Barbara Slusher, Rana Rais, James Vornov

Keywords(s): Chronic Pain, CNS and Neurological Disorders, Disease Indication, Migraine, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Neurology > Migraine, Clinical and Disease Specializations > Pain, Clinical and Disease Specializations > Pain > Chronic Pain, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

1 2